Peptide record

TPDB92026

Transportan 10 Antibacterial Anticancer Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity modified_plain modified
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92026
Transportan 10
Antibacterial Anticancer Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP Peptipedia Antifungipept CAFPdb dbAMP 3.0 i2APP B3Pred BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP HemoPI Hemolytic2 PD_Hemolysis
modified_plain
Yes
A 21-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
C-terminal: Amide group is attached
Sequence
AGYLLGKINLKALAALAKKIL
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
21 reviewed residue count
Amide group is attached Activity
Linear Activity
Cationic Activity
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu Activity
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O Activity
Evidence Records 15 records
Evidence 1 Activity

Activity

Blood-Brain Barrier
6.3 ± 1.3 micromolar

Target

S. aureus MRSA N315

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Alone
Evidence 2 Activity

Activity

Blood-Brain Barrier
12.5 ± 3.2 micromolar

Target

S. aureus MRSA N315

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows the resistance
Alone
Evidence 3 Activity

Activity

Blood-Brain Barrier
6.3 ± 1.6 micromolar

Target

S. aureus MRSA N315

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Alone
Evidence 4 Activity

Activity

Blood-Brain Barrier
6.3 ± 1.6 micromolar

Target

S. aureus MRSA 12673

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 5 Activity

Activity

Blood-Brain Barrier
0.8 ± 0.4 micromolar

Target

S. aureus MRSA 12673

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows high sensitivity
Combined with Vanomycin
Evidence 6 Activity

Activity

Blood-Brain Barrier
0.8 ± 0.3 micromolar

Target

S. aureus MRSA 12673

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows high sensitivity
Combined with Vanomycin
Evidence 7 Activity

Activity

Blood-Brain Barrier
12.5 ± 3.2 micromolar

Target

S. aureus MRSA hetero-VISA 6347b

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows high sensitivity
Combined with Vanomycin
Evidence 8 Activity

Activity

Blood-Brain Barrier
1.6 ± 0.4 micromolar

Target

S. aureus MRSA hetero-VISA 6347b

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 9 Activity

Activity

Blood-Brain Barrier
3.1 ± 0.8 micromolar

Target

S. aureus MRSA hetero-VISA 6347b

Assay & Model

100000 CFU/mL
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 10 Activity

Activity

Blood-Brain Barrier
12.5 ± 3.4 micromolar

Target

Enterococcus faecium 3934825

Assay & Model

60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 11 Activity

Activity

Blood-Brain Barrier
12.5 ± 3.2 micromolar

Target

Enterococcus faecium 3934825

Assay & Model

60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 12 Activity

Activity

Blood-Brain Barrier
6.3 ± 1.7 micromolar

Target

Enterococcus faecium 3934825

Assay & Model

60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 13 Activity

Activity

Blood-Brain Barrier
12.5 ± 2.2 micromolar

Target

Enterococcus faecalis 3937158

Assay & Model

60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 14 Activity

Activity

Blood-Brain Barrier
25.0 ± 5.1 micromolar

Target

Enterococcus faecalis 3937158

Assay & Model

60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows the resistance
Combined with Vanomycin
Evidence 15 Activity

Activity

Blood-Brain Barrier
25.0 ± 6.9 micromolar

Target

Enterococcus faecalis 3937158

Assay & Model

60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows the resistance
Combined with Vanomycin
Additional Detail Fields 1 fields
Intravenous